Home  >  News
you can get e-magazine links on WhatsApp. Click here
Product Launches + Font Resize -

Rusan Pharma launches DCGI approved Aposan to treat patients with Parkinson’s disease

Our Bureau, Mumbai
Friday, December 14, 2018, 14:30 Hrs  [IST]

Rusan Pharma, a fully integrated global pharmaceutical company specializing in the treatment of 'Addiction and Pain Management', announced the launch of DCGI approved Aposan (apomorphine hydrochloride (HCl).

According to a company release, Aposan is India’s first product to be indigenously developed and manufactured by Rusan. Aposan is used for the treatment of motor fluctuations (“ON-OFF”) in patients with Parkinson’s disease (PD) which are not sufficiently controlled by oral anti-Parkinson’s medication currently available in India. Aposan will be available in the form of injections, pen and continuous infusion pumps.

PD is a long-term degenerative disorder of the central nervous system (CNS) that mainly affects the motor system. PD is also one of the most common neurodegenerative diseases affecting the aging population and is associated with increased morbidity and mortality. It eventually causes severe disability due to the increasing severity of treatment-resistant motor problems and non-motor symptoms. Despite it’s name, apomorphine as a molecule is structurally not similar to morphine and is hence not a controlled or addictive medicine.

The economic burden related to PD in India will continue to escalate. As per global, regional and national burden of PD, in 2016, the deaths due to PD in India were 17,539; prevalence is 5,75,946 and over 3 lakh people with Disability Adjusted Life Years (DALY’s).

Currently, in India only oral treatments such as levodopa & carbidopa combinations are used. In the PD patients, the gastrointestinal system is compromised, resulting in side effects such as absorption issues, constipation and dysphagia (swallowing difficulties). As a result, the optimization of oral treatment in moderate to advanced PD patients is a challenge that may lead to sub-optimal response, delayed time to “ON” or dosage failure. To overcome these challenges, injectable form of apomorphine has been the need of the hour.

Apomorphine has a reliable, rapid onset of action (4-10 minutes) and the duration of action is upto 60 to 90 minutes. Apomorphine is the most efficacious drug for not just managing the motor fluctuations (OFFàON) but also non-motor symptoms of Parkinson’s disease such as sleep problems, depression, anxiety, pain and urinary dysfunction. Studies show that 68% of the patients report reduction in hallucinations. 58% of the patients reported a reduction of ‘OFF’ time (both duration and severity of dyskinesia). 85% reported improvement in night time sleep problems from insomnia, and hypersomnia to rapid eye movement (REM).

Commenting on the launch, Dr Kunal Saxena, MD, Rusan Pharma said, “Rusan, has always put forward indigenously developed high technology advanced delivery products in the Indian market. Being a Make in India product, we want to ensure the treatment is affordable and accessible to all PD patients. Since, PD is a chronic disease, we aim to bring the per day cost to patients down to an affordable price. With Aposan, the cost of the product for a daily dose (between 30 – 60 mg), in India will range between Rs. 475 to Rs. 950 per day as compared to apomorphine pens in the UK ranging between Rs. 2,250 to Rs. 4,500 per day. To make the therapy even more affordable and ensuring ease of use, we will be launching the Aposan pens and Aposan continuous infusion pumps which will be provided free of cost to the patients with Rusan’s Aposan therapy. Aposan will be available pan India by January 2019. With the Aposan therapy, Rusan will also be launching the Aposan Hope Programme which will comprise of Hope Nurses who will offer support free of cost to doctors, nurses, patients and their caregivers on the safe and effective use of the Aposan range of products.”


* Name :     
* Email :    
  Website :  
vijayakrishnan Sep 3, 2020 4:33 PM
kindly share the article for Apomorphine as controlled subtance in india.
Apollo Clinical Research
Copyright © 2016 Saffron Media Pvt. Ltd |